15 Large Cap Stocks Under $30 With Huge Upside Potential

8. Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 15 large cap stocks under $30 with huge upside potential.

As of the March 23 closing, consensus sentiment for Genmab A/S (NASDAQ:GMAB) remained strongly bullish. The stock received coverage from 9 analysts, 7 of whom assigned Buy ratings and 2 gave Hold calls. With no Sell rating, it has a projected median 1-year price target of $39.25, resulting in an upside potential of almost 53% at the prevailing level.

On March 2, Wells Fargo began coverage of Genmab A/S (NASDAQ:GMAB). The firm assigned an Overweight rating to the stock, with a target price of $40. This results in an upside potential of almost 56% at the current level.

Based on Phase 2 data, the firm highlighted that the company’s impending Epkinly and petosemtamab readouts are substantially de-risked. Furthermore, Genmab A/S (NASDAQ:GMAB) shares at current levels do not represent petosemtamab’s potential outside head and neck cancer. According to Wells Fargo, 2026 will be a pivotal year for the company due to several factors.

Back on February 23, Genmab A/S (NASDAQ:GMAB) was subject to a target price reduction by Guggenheim analyst Michael Schmidt. The analyst lowered the firm’s target from $45 to $40, while reiterating his Buy rating on the stock. Schmidt attributed this downward revision to a deflated outlook for Epkinly, in the near term.

Genmab A/S (NASDAQ:GMAB) is a biotechnology company based in Denmark that develops antibodies and related products to treat cancer and other diseases. The company markets various cures for adults, including EPKINLY, TEPKINLY, and Tivdak.